Functions of the Epstein-Barr virus EBNA1 protein in viral reactivation and lytic infection

Journal of Virology

Volumn 86, Issue 11, 2012, Pages 6146-6158

  Sivachandran, Nirojini ^a   Wang, Xueqi ^a   Frappier, Lori ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CHEMOKINE; BMRF1 PROTEIN; EPSTEIN BARR VIRUS ANTIGEN 1; IMMEDIATE EARLY PROTEIN BZLF1; PROMYELOCYTIC LEUKEMIA PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VIRUS PROTEIN; EBV ENCODED NUCLEAR ANTIGEN 1; EBV-ENCODED NUCLEAR ANTIGEN 1; EPSTEIN BARR VIRUS ANTIGEN; NUCLEAR PROTEIN; PML PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CANCER CELL CULTURE; CELL NUCLEUS INCLUSION BODY; CONTROLLED STUDY; EPITHELIUM CELL; EPSTEIN BARR VIRUS; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; GENE SILENCING; LATENT VIRUS INFECTION; NASOPHARYNX CARCINOMA; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN DEGRADATION; RNA TRANSCRIPTION; STOMACH CARCINOMA; VIRUS INFECTION; VIRUS INHIBITION; VIRUS LYTIC INFECTION; VIRUS REACTIVATION; GROWTH, DEVELOPMENT AND AGING; HUMAN; METABOLISM; PHYSIOLOGY; VIROLOGY; VIRUS ACTIVATION; VIRUS REPLICATION;

HUMAN HERPESVIRUS 4;

EPITHELIAL CELLS; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; HERPESVIRUS 4, HUMAN; HUMANS; NUCLEAR PROTEINS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS; VIRUS ACTIVATION; VIRUS REPLICATION;

EID: 84863599916     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00013-12     Document Type: Article

References (78)

1. Adams A. 1987. Replication of latent Epstein-Barr virus genomes. J. Virol. 61:1743-1746.
2. Adamson AL, Kenney S. 2001. Epstein-Barr virus immediate-early protein BZLF1 is SUMO-1 modified and disrupts promyelocytic leukemia bodies. J. Virol. 75:2388-2399.
3. Ahn JH, Hayward GS. 2000. Disruption of PML-associated nuclear bodies by IE1 correlates with efficient early stages of viral gene expression and DNA replication in human cytomegalovirus infection. Virology 274:39-55.
4. Ahsan N, Kanda T, Nagashima K, Takada K. 2005. Epstein-Barr virus transforming protein LMP1 plays a critical role in virus production. J. Virol. 79:4415-4424.
5. Bell P, Lieberman PM, Maul GG. 2000. Lytic but not latent replication of Epstein-Barr virus is associated with PML and induces sequential release of nuclear domain 10 proteins. J. Virol. 74:11800-11810.
6. Bernardi R, Pandolfi PP. 2007. Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat. Rev. Mol. Cell Biol. 8:1006-1016.
7. Brink AA, Meijer CJ, Nicholls JM, Middeldorp JM, van den Brule AJ. 2001. Activity of the EBNA1 promoter associated with lytic replication (Fp) in Epstein-Barr virus associated disorders. Mol. Pathol. 54:98-102.
8. Cochet C, et al. 1993. Expression of the Epstein-Barr virus immediate early gene, BZLF1, in nasopharyngeal carcinoma tumor cells. Virology 197:358-365.
9. Condemine W, et al. 2006. Characterization of endogenous human promyelocytic leukemia isoforms. Cancer Res. 66:6192-6198.
10. Cuchet D, et al. 2011. PML isoforms I and II participate in PMLdependent restriction of HSV-1 replication. J. Cell Sci. 124:280-291.
11. Daikoku T, et al. 2004. In vivo dynamics of EBNA1-oriP interaction during latent and lytic replication of Epstein-Barr virus. J. Biol. Chem. 279:54817-54825.
12. Deng Z, et al. 2005. Inhibition of Epstein-Barr virus OriP function by tankyrase, a telomere-associated poly-ADP ribose polymerase that binds and modifies EBNA1. J. Virol. 79:4640-4650.
13. Everett RD. 2001. DNA viruses and viral proteins that interact with PML nuclear bodies. Oncogene 20:7266-7273.
14. Everett RD. 2006. Interactions between DNA viruses, ND10 and the DNA damage response. Cell Microbiol. 8:365-374.
15. Everett RD, Chelbi-Alix MK. 2007. PML and PML nuclear bodies: implications in antiviral defence. Biochimie 89:819-830.
16. Everett RD, et al. 1998. The disruption of ND10 during herpes simplex virus infection correlates with the Vmw110-and proteasome-dependent loss of several PML isoforms. J. Virol. 72:6581-6591.
17. Everett RD, Murray J. 2005. ND10 components relocate to sites associated with herpes simplex virus type 1 nucleoprotein complexes during virus infection. J. Virol. 79:5078-5089.
18. Everett RD, et al. 2006. PML contributes to a cellular mechanism of repression of herpes simplex virus type 1 infection that is inactivated by ICP0. J. Virol. 80:7995-8005.
19. Everett RD, Young DF, Randall RE, Orr A. 2008. STAT-1-and IRF-3-dependent pathways are not essential for repression of ICP0-null mutant herpes simplex virus type 1 in human fibroblasts. J. Virol. 82:8871-8881.
20. Feederle R, et al. 2000. The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators. EMBO J. 19:3080-3089.
21. Fixman ED, Hayward GS, Hayward SD. 1992. trans-acting requirements for replication of Epstein-Barr virus ori-Lyt. J. Virol. 66:5030-5039.
22. Fogal V, et al. 2000. Regulation of p53 activity in nuclear bodies by a specific PML isoform. EMBO J. 19:6185-6195.
23. Fukayama M. 2010. Epstein-Barr virus and gastric carcinoma. Pathol. Int. 60:337-350.
24. Gabelova A, et al. 2007. Sensitivity of different endpoints for in vitro measurement of genotoxicity of extractable organic matter associated with ambient airborne particles (PM10). Mutat. Res. 620:103-113.
25. Gahn T, Sugden B. 1995. An EBNA1 dependent enhancer acts from a distance of 10 kilobase pairs to increase expression of the Epstein-Barr virus LMP gene. J. Virol. 69:2633-2636.
26. Gao Z, et al. 1998. The Epstein-Barr virus lytic transactivator Zta interacts with the helicase-primase replication proteins. J. Virol. 72:8559-8567.
27. Geoffroy MC, Chelbi-Alix MK. 2011. Role of promyelocytic leukemia protein in host antiviral defense. J. Interferon Cytokine Res. 31:145-158.
28. Glaser R, et al. 1989. Two epithelial tumor cell lines (HNE-1 and HONE-1) latently infected with Epstein-Barr virus that were derived from nasopharyngeal carcinomas. Proc. Natl. Acad. Sci. U. S. A. 86:9524-9528.
29. Guo A, et al. 2000. The function of PML in p53-dependent apoptosis. Nat. Cell Biol. 2:730-736.
30. Holowaty MN, et al. 2003. Protein profiling with Epstein-Barr nuclear antigen-1 reveals an interaction with the herpesvirus-associated ubiquitin-specific protease HAUSP/USP7. J. Biol. Chem. 278:29987-29994.
31. Hong GK, et al. 2005. Epstein-Barr virus lytic infection contributes to lymphoproliferative disease in a SCID mouse model. J. Virol. 79:13993-14003.
32. Hong GK, et al. 2005. Epstein-Barr virus lytic infection is required for efficient production of the angiogenesis factor vascular endothelial growth factor in lymphoblastoid cell lines. J. Virol. 79:13984-13992.
33. Hoppe A, Beech SJ, Dimmock J, Leppard KN. 2006. Interaction of the adenovirus type 5 E4 Orf3 protein with promyelocytic leukemia protein isoform II is required for ND10 disruption. J. Virol. 80:3042-3049.
34. Jenkins PJ, Binne UK, Farrell PJ. 2000. Histone acetylation and reactivation of Epstein-Barr virus from latency. J. Virol. 74:710-720.
35. Kennedy G, Komano J, Sugden B. 2003. Epstein-Barr virus provides a survival factor to Burkitt's lymphomas. Proc. Natl. Acad. Sci. U. S. A. 100:14269-14274.
36. Kenney SC. 2007. Reactivation and lytic replication of EBV. In Arvin A, et al (ed), Human herpesviruses: biology, therapy, and immunoprophylaxis. Cambridge University Press, Cambridge, United Kingdom.
37. Kolman JL, Taylor N, Gradoville L, Countryman J, Miller G. 1996. Comparing transcriptional activation and autostimulation by ZEBRA and ZEBRA/c-Fos chimeras. J. Virol. 70:1493-1504.
38. Lear AL, et al. 1992. The Epstein-Barr virus (EBV) nuclear antigen 1 BamHI F promoter is activated on entry of EBV-transformed B cells into the lytic cycle. J. Virol. 66:7461-7468.
39. Lieberman PM, Hardwick JM, Sample J, Hayward GS, Hayward SD. 1990. The zta transactivator involved in induction of lytic cycle gene expression in Epstein-Barr virus-infected lymphocytes binds to both AP-1 and ZRE sites in target promoter and enhancer regions. J. Virol. 64:1143-1155.
40. Maroui MA, Pampin M, Chelbi-Alix MK. 2011. Promyelocytic leukemia isoform IV confers resistance to encephalomyocarditis virus via the sequestration of 3D polymerase in nuclear bodies. J. Virol. 85:13164-13173.
41. McNally BA, Trgovcich J, Maul GG, Liu Y, Zheng P. 2008. A role for cytoplasmic PML in cellular resistance to viral infection. PLoS One 3:e2277.
42. Miller G, El-Guindy A, Countryman J, Ye J, Gradoville L. 2007. Lytic cycle switches of oncogenic human gammaherpesviruses(1). Adv. Cancer Res. 97:81-109.
43. Moser MS, Abu-Laban RB, van Beek CA. 2004. Attitude of emergency department patients with minor problems to being treated by a nurse practitioner. CJEM 6:246-252.
44. Nojima T, et al. 2009. Herpesvirus protein ICP27 switches PML isoform by altering mRNA splicing. Nucleic Acids Res. 37:6515-6527.
45. Pearson M, et al. 2000. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 406:207-210.
46. Raab-Traub N. 2002. Epstein-Barr virus in the pathogenesis of NPC. Semin. Cancer Biol. 12:431-441.
47. Rawlins DR, Milman G, Hayward SD, Hayward GS. 1985. Sequencespecific DNA binding of the Epstein-Barr virus nuclear antigen (EBNA1) to clustered sites in the plasmid maintenance region. Cell 42:859-868.
48. Reichelt M, et al. 2011. Entrapment of viral capsids in nuclear PML cages is an intrinsic antiviral host defense against varicella-zoster virus. PLoS Pathog. 7:e1001266.
49. Reisman D, Sugden B. 1986. trans activation of an Epstein-Barr viral transcriptional enhancer by the Epstein-Barr viral nuclear antigen 1. Mol. Cell. Biol. 6:3838-3846.
50. Rickinson AB, Kieff E. 1996. Epstein-Barr virus, p 2397-2446. In Fields BN, Knipe DM, Howley PM (ed), Fields virology, 3rd ed. Lippincott-Raven Publishers, Philadelphia, PA.
51. Salomoni P, Ferguson BJ, Wyllie AH, Rich T. 2008. New insights into the role of PML in tumour suppression. Cell Res. 18:622-640.
52. Salsman J, Zimmerman N, Chen T, Domagala M, Frappier L. 2008. Genome-wide screen of three herpesviruses for protein subcellular localization and alteration of PML nuclear bodies. PLoS Pathog. 4:e1000100.
53. Saridakis V, et al. 2005. Structure of the p53 binding domain of HAUSP/USP7 bound to Epstein-Barr nuclear antigen 1: implications for EBVmediated immortalization. Mol. Cell 18:25-36.
54. Sarkari F, et al. 2009. EBNA1-mediated recruitment of a histone H2B deubiquitylating complex to the Epstein-Barr virus latent origin of DNA replication. PLoS Pathog. 5:e1000624.
55. Sarkari F, Wang X, Nguyen T, Frappier L. 2011. The herpesvirus associated ubiquitin specific protease, USP7, is a negative regulator of PML proteins and PML nuclear bodies. PLoS One 6:e16598.
56. Scaglioni PP, et al. 2006. A CK2-dependent mechanism for degradation of the PML tumor suppressor. Cell 126:269-283.
57. Scaglioni PP, et al. 2008. CK2 mediates phosphorylation and ubiquitinmediated degradation of the PML tumor suppressor. Mol. Cell. Biochem. 316:149-154.
58. Schaefer BC, Strominger JL, Speck SH. 1995. The Epstein-Barr virus BamHI F promoter is an early lytic promoter: lack of correlation with EBNA1 gene transcription in group 1 Burkitt's lymphoma cell lines. J. Virol. 69:5039-5047.
59. Shannon-Lowe C, et al. 2009. Features distinguishing Epstein-Barr virus infections of epithelial cells and B cells: viral genome expression, genome maintenance, and genome amplification. J. Virol. 83:7749-7760.
60. Sides MD, et al. 2011. Arsenic mediated disruption of promyelocytic leukemia protein nuclear bodies induces ganciclovir susceptibility in Epstein-Barr positive epithelial cells. Virology 416:86-97.
61. Sivachandran N, Cao JY, Frappier L. 2010. Epstein-Barr virus nuclear antigen 1 hijacks the host kinase CK2 to disrupt PML nuclear bodies. J. Virol. 84:11113-11123.
62. Sivachandran N, et al. 2012. Contributions of the Epstein-Barr virus EBNA1 protein to gastric carcinoma. J. Virol. 86:60-68.
63. Sivachandran N, Sarkari F, Frappier L. 2008. Epstein-Barr nuclear antigen 1 contributes to nasopharyngeal carcinoma through disruption of PML nuclear bodies. PLoS Pathog. 4:e1000170.
64. Stewart S, et al. 2004. Epstein-Barr virus-encoded LMP2A regulates viral and cellular gene expression by modulation of the NF-kappaB transcription factor pathway. Proc. Natl. Acad. Sci. U. S. A. 101:15730-15735.
65. Sun Y, et al. 1992. An infrequent point mutation of the p53 gene in human nasopharyngeal carcinoma. Proc. Natl. Acad. Sci. U. S. A. 89: 6516-6520.
66. Tao Q, Chan AT. 2007. Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments. Expert Rev. Mol. Med. 9:1-24.
67. Tavalai N, Papior P, Rechter S, Leis M, Stamminger T. 2006. Evidence for a role of the cellular ND10 protein PML in mediating intrinsic immunity against human cytomegalovirus infections. J. Virol. 80:8006-8018.
68. Tavalai N, Stamminger T. 2011. Intrinsic cellular defense mechanisms targeting human cytomegalovirus. Virus Res. 157:128-133.
69. Wang S, Frappier L. 2009. Nucleosome assembly proteins bind to Epstein-Barr virus nuclear antigen 1 and affect its functions in DNA replication and transcriptional activation. J. Virol. 83:11704-11714.
70. Wen W, et al. 2007. Epstein-Barr virus BZLF1 gene, a switch from latency to lytic infection, is expressed as an immediate-early gene after primary infection of B lymphocytes. J. Virol. 81:1037-1042.
71. Wu H, Kapoor P, Frappier L. 2002. Separation of the DNA replication, segregation, and transcriptional activation functions of Epstein-Barr nuclear antigen 1. J. Virol. 76:2480-2490.
72. Yates JL, Guan N. 1991. Epstein-Barr virus-derived plasmids replicate only once per cell cycle and are not amplified after entry into cells. J. Virol. 65:483-488.
73. Yates JL, Warren N, Reisman D, Sugden B. 1984. A cis-acting element from the Epstein-Barr viral genome that permits stable replication of re-combinant plasmids in latently infected cells. Proc. Natl. Acad. Sci. U. S. A. 81:3806-3810.
74. Yates JL, Warren N, Sugden B. 1985. Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature 313: 812-815.
75. Yin Q, Flemington EK. 2006. siRNAs against the Epstein Barr virus latency replication factor, EBNA1, inhibit its function and growth of EBVdependent tumor cells. Virology 346:385-393.
76. Yuan J, Cahir-McFarland E, Zhao B, Kieff E. 2006. Virus and cell RNAs expressed during Epstein-Barr virus replication. J. Virol. 80:2548-2565.
77. Zetterberg H, Stenglein M, Jansson A, Ricksten A, Rymo L. 1999. Relative levels of EBNA1 gene transcripts from the C/W, F andQpromoters in Epstein-Barr virus-transformed lymphoid cells in latent and lytic stages of infection. J. Gen. Virol. 80(Pt 2):457-466.
78. Zhou J, Snyder AR, Lieberman PM. 2009. Epstein-Barr virus episome stability is coupled to a delay in replication timing. J. Virol. 83:2154-2162.